Free Trial

Xenon Pharmaceuticals Q4 2022 Earnings Report

Xenon Pharmaceuticals logo
$41.33 +0.05 (+0.12%)
(As of 10:21 AM ET)

Xenon Pharmaceuticals EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.58
Beat/Miss
Beat by +$0.01
One Year Ago EPS
-$0.57

Xenon Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.46 million
Beat/Miss
N/A
YoY Revenue Growth
-100.00%

Xenon Pharmaceuticals Announcement Details

Quarter
Q4 2022
Time
After Market Closes

Conference Call Resources

Conference Call Audio

AI Crypto Tool Could Send One Coin SOARING… (Ad)

The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto project

Discover our #1 crypto pick before it's too late.

Xenon Pharmaceuticals Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
See More Xenon Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xenon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenon Pharmaceuticals and other key companies, straight to your email.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

View Xenon Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings